Mablink Bioscience is a French-based biotechnology company specialized in the development of an emerging class of cancer drugs, called antibody-drug conjugate (ADC). Mablink leverages its patented hydrophilic technology PSARlink™ that enables the design of homogenous, plasma-stable next generation ADCs with high DAR, whilst retaining excellent pharmacological properties, in order to quickly bring new and better treatment options to cancer patients.
Location: France, Auvergne-Rhône-Alpes, Lyon
Employees: 11-50
Total raised: $34.97M
Founded date: 2018
Investors 3
| Date | Name | Website |
| 21.03.2022 | Turenne Ca... | turennecap... |
| 27.04.2021 | Elaia Part... | elaia.com |
| 27.10.2022 | Korys | korys.be |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 14.10.2022 | Series A | $30.13M | - |
| 27.04.2021 | Seed | $4.84M | - |
Mentions in press and media 6
| Date | Title | Description | Source |
| 13.03.2024 | As European dynamism gathers momentum, Elaia and partners do... | Deep tech is on the rise in Europe, fueled in part by the match between AI and a local flavor of mat... | techcrunch... |
| 27.04.2021 | Mablink Bioscience : the next generation ADC company, raises... | LYON, France, April 27, 2021 /PRNewswire/ -- Mablink Bioscience, a company developing the next gener... | marketscre... |
| 27.04.2021 | Mablink Bioscience Raises €4M in Seed Funding | Mablink Bioscience, a Lyon, France-based company developing antibody-drug conjugates (ADC), complete... | finsmes.co... |
| 27.04.2021 | Mablink Bioscience, the next generation ADC company, raises ... | prnewswire... | |
| - | Mablink Bioscience, l’expert des ADC nouvelle génération, lè... | (27/04/2020) Mablink Bioscience va développer son pipeline d’ADC dirigés contre des cancers avec peu... | sofimacinn... |
| - | Mablink Bioscience | “Mablink develops antibody-drug conjugate (ADC) using its patented PSARlink™ technology to bring bet... | fastfounde... |